GVR Report cover Molecular Biology Enzymes, Reagents And Kits Market Size, Share & Trends Report

Molecular Biology Enzymes, Reagents And Kits Market Size, Share & Trends Analysis Report By Product, By Application (Restriction Digestion, Sequencing, Cloning), By End-use, By Region, And Segment Forecasts, 2020 - 2027

  • Report ID: GVR-4-68039-913-4
  • Number of Pages: 275
  • Format: Electronic (PDF)
  • Historical Range: 2016 - 2018
  • Industry: Healthcare

Report Overview 

The global molecular biology enzymes, reagents and kits market size was valued at USD 12.7 billion in 2019 and is expected to expand at a compound annual growth rate (CAGR) of 11.0% from 2020 to 2027. Constant technological advancements in the molecular biology field have significantly impacted the life sciences investigations carried out for the management of medical conditions, thereby driving the usage of molecular biology consumables. In addition, the advent of precise computational tools coupled with continuous updating biological databases further propels the adoption rate of solutions offered in the market for molecular biology enzymes, reagents, and kits. Omics technology and systems biology are among the common emerging concepts of molecular medicine. Analysis of multi-omics-based technologies through systems biology, computational power, and bioinformatics assist the researchers to better understand the disease diversity, disease progression, molecular heterogeneity of sophisticated pathologies, and drug resistance.

U.K. molecular biology enzymes, reagents & kits market size

Therefore, a rise in omics-based research studies drives the demand for molecular enzymes, reagents, and kits. The advancements in technology and scientific studies have played a vital role in shaping the product landscape, resulting in the introduction of new guidelines for these new technologies. Common primary federal agencies, such as the Food and Drug Administration (FDA) and the World Health Organization, assess and manage potential environmental and health risks related to these products. These factors promote the usage of products offered under this market for molecular biology enzymes, reagents, and kits.

Moreover, the emergence of single-cell genome sequencing that offers a viable solution for effective assessment of biomolecules, including RNA, DNA, chromatin, and protein, has accelerated revenue growth. Isolation of these molecules from a single cell for advanced molecular profiling enables a better understanding of biological diversity. This expands the sequencing landscape and further creates lucrative opportunities for operating players to capitalize on the avenues by providing reagents and kits to support single-cell sequencing.

Besides, constant development in restriction enzymes with respect to specificity and efficiency is one of the key driving forces of the market for molecular biology enzymes and reagents and kits. This is because these enzymes play an important role in the physical mapping of DNA across several applications such as DNA fingerprinting and methylation analysis. Research studies have indicated the broad utilization of this enzyme for characterization of single cells, genomic and epigenomic studies, subsequently propelling the growth of the market for molecular biology enzymes and reagents and kits.

Product Insights

Kits and reagents dominated the market for molecular biology enzymes and reagents and kits with a revenue share of 68.5% in 2019. This is due to the wide availability of kits and reagents and novel product developments by key companies. For instance, in March 2019, Asuragen, Inc. introduced the AmplideX PCR/CE SMN1/2 Kit that offers a reliable and rapid technique for the detection of SMN2 and SMN1 exon 7 copy number within 4 hours. It is based on a Polymerase Chain Reaction (PCR) and is used for molecular diagnostic purposes.

An exponential rise in the number of COVID-19 cases globally has encouraged biotechnology and healthcare companies to accelerate the production of RT-PCR-based testing kits. As reported in March 2020, Thermo Fisher stated that it has planned to generate up to 5.0 million new tests for the detection of COVID-19. Therefore, an increase in the commercial availability of COVID-19 testing products is expected to drive the demand for kits and reagents used in COVID-19 diagnosis. Enzymes such as Proteinases are used in the diagnosis and have gained momentum as a consequence of the pandemic.

Furthermore, the continuous expansion of cloning technology as a routine laboratory technology has allowed manufacturers to provide numerous enzymes for the generation and manipulation of nucleic acids. This technology has progressed from single DNA fragment cloning to the assembly of multiple DNA fragments into a single contiguous DNA stretch. Therefore, advancement in cloning technology influences the growth of molecular biology enzymes at a lucrative pace during the forecast period.

Application Insights

The sequencing segment accounted for the major revenue share of 34.9% in 2019 in the molecular biology enzymes, reagents and kits market. The segment is expected to grow at a lucrative pace. With the introduction of Next-generation Sequencing (NGS), there has been tremendous progress in genetic research and the discovery of human diseases. NGS analysis of tumor epigenomics, genomics, and transcriptomics, drives biomarker discovery for cancer diagnostics and tumor stratification.

The benefits of NGS include detection of the smallest possible mutation, easier combined detection of SNP and larger abnormalities, and most important combination of high-throughput, speed, and resolution. Moreover, a rise in the adoption of personalized medicine through targeted and whole-exome sequencing is expected to drive the demand for sequencing. Thereby, widespread adoption of these technologies accelerates the utilization of molecular biology products under this segment.

In terms of revenue, PCR captured the second-largest revenue share in 2019 in the market for molecular biology enzymes, reagents, and kits. The advent of miniPCR in recent times has made the technique affordable and more portable. On the other hand, the introduction of the droplet digital PCR (ddPCR), which integrates conventional PCR with the fluorescence-activated cell sorting aspects, offers a highly automated and robust technology for the detection of scarce targets in samples. Such advances in PCR technology are expected to drive revenue in this segment.

End-use Insights

The pharma and biotech segment dominated the market for molecular biology enzymes and reagents and kits and accounted for the largest revenue share of 36.3% in 2019. An increase in the R&D activities and several ongoing clinical trials in the pharma and biotech firms are driving the demand for molecular biology enzymes and reagents. Furthermore, shifting preferences towards personalized medicine and companion diagnostic has propelled collaborations and mergers with respect to sequencing technology, which subsequently surges the demand for sequencing products.

Global molecular biology enzymes, kits & reagents market share

For instance, QIAGEN entered into a 15-year partnership with Illumina, Inc. to broaden the use of NGS-based in vitro diagnostic kits for patient management in October 2019. This collaboration offers QIAGEN with an opportunity to develop companion diagnostic tests for the evaluation of tumors for potential immunotherapies on the TruSight Oncology assays from Illumina. Such initiatives are also expected to fuel the segment growth at a lucrative pace in the market for molecular biology enzymes, reagents, and kits.

Wide applications of NGS and PCR techniques in academic research projects accelerate the uptake of these products by universities and research centers. As reported in March 2020, researchers at the UNC Medical Center Microbiology and Molecular Microbiology Laboratories explored the usage of NGS for accurate COVID-19 diagnosis. Moreover, arise in funding and investment for these entities are expected to augment the academic and research segment at a considerable CAGR.

Regional Insights

North America dominated the market for molecular biology enzymes, reagents, and kits and accounted for the largest revenue share of 45.5% in 2019. Initiatives, such as the Newborn Sequencing in Genomic Medicine and Public Health program by the National Human Genome Research Institute to screen infants for genetic diseases, boost the implementation of NGS technology and its associated reagents and kits. 

The U.S.-based companies are undertaking focused efforts to develop technologically advanced products for molecular biology techniques that consequently drive the market for molecular biology enzymes, reagents, and kits in the region. For instance, in May 2019, Pharmozyme, Inc., launched Crystal Taq, which is a cost-effective solution with improved test accuracy. This is the first Taq Polymerase enzyme free from bacterial and animal DNA contamination and reduces PCR background contamination.

In the Asia Pacific, the market for molecular biology enzymes, reagents, and kits is projected to register a lucrative growth rate during the forecast period. Continual development and commercialization of point of care PCR equipment and reagents by the regional players are one of the primary factors influencing the growth of the market in the region. For instance, in May 2020, Fujifilm Wako Pure Chemical Corp., a Japan-based firm, initiated the commercialization of PCR reagents for the automated coronavirus test device. 

Key Companies & Market Share Insights

Molecular biology enzymes, reagents, and kits have gained the interest of several companies, scientific communities, and investors for a wide range of applications, such as PCR, sequencing, cloning, and synthetic biology. The companies are continuously expanding their technology portfolios to make these products more widely available, user-friendly, innovative, and affordable. For instance, in January 2020, Agilent Technologies introduced the Agilent SureSelect XT HS2 DNA Kit, which is designed to overcome the challenges faced by researchers during the preparation of DNA sequencing libraries. This new product allows the researchers to select the workflow that better suit their requirements. This product development is expected to accelerate the company’s capture-based enrichment library preparation activities. Some of the prominent players in the molecular biology enzymes, reagents and kits market include: 

  • Thermo Fisher Scientific, Inc.


  • Illumina, Inc.

  • F. Hoffmann-La Roche Ltd.

  • Agilent Technologies, Inc.

  • Bio-Rad Laboratories, Inc.

  • New England Biolabs

  • Merck KGaA

  • Promega Corporation

  • Takara Bio, Inc.

  • LGC Limited

Molecular Biology Enzymes, Reagents And Kits Market Report Scope

Report Attribute


Market size value in 2020

USD 14.9 billion

Revenue forecast in 2027

USD 29.3 billion

Growth rate

CAGR of 11.0% from 2020 to 2027

Base year for estimation


Historical data

2016 - 2018

Forecast period

2020 - 2027

Quantitative units

Revenue in USD million and CAGR from 2020 to 2027

Report coverage

Revenue forecast, company share, competitive landscape, growth factors, and trends

Segments covered

Product, application, end-use, region

Regional scope

North America; Europe; Asia Pacific; Latin America; Middle East & Africa

Country scope

U.S.; Canada; Germany; U.K.; France; Spain; Italy; China; Japan; India; Australia; Brazil; Mexico; South Africa

Key companies profiled

Thermo Fisher Scientific, Inc.; QIAGEN; Illumina, Inc.; F. Hoffmann-La Roche Ltd.; Agilent Technologies, Inc.; Bio-Rad Laboratories, Inc.; New England Biolabs; Merck KGaA; Promega Corporation; Takara Bio, Inc.; LGC Limited

Customization scope

Free report customization (equivalent up to 8 analyst’s working days) with purchase. Addition or alteration to country, regional & segment scope.

Pricing and purchase options

Avail customized purchase options to meet your exact research needs. Explore purchase options

Segments Covered in the Report

This report forecasts revenue growth at global, regional, and country levels and provides an analysis of the latest industry trends in each of the sub-segments from 2016 to 2027. For the purpose of this study, Grand View Research has segmented the global molecular biology enzymes, reagents and kits market report on the basis of product, application, end-use, and region:

  • Product Outlook (Revenue, USD Million, 2016 - 2027)

    • Kits & Reagents

    • Enzymes

  • Application Outlook (Revenue, USD Million, 2016 - 2027)

    • Cloning

    • Sequencing

    • PCR

    • Epigenetics

    • Restriction Digestion

    • Other Applications

  • End-use Outlook (Revenue, USD Million, 2016 - 2027)

    • Pharma & Biotech

    • Academic & Research

    • Hospital & Diagnostics

    • Others

  • Regional Outlook (Revenue, USD Million, 2016 - 2027)

    • North America

      • The U.S.

      • Canada

    • Europe

      • Germany

      • The U.K.

      • France

      • Italy

      • Spain

    • Asia Pacific

      • China

      • Japan

      • India

      • Australia

    • Latin America

      • Brazil

      • Mexico

    • Middle East & Africa (MEA)

      • South Africa

Frequently Asked Questions About This Report




This FREE sample includes market data points, ranging from trend analyses to market estimates & forecasts. See for yourself.



We can customize every report - free of charge - including purchasing stand-alone sections or country-level reports, as well as offer affordable discounts for start-ups & universities.

Contact us now to get our best pricing.

BBB icon gvr sidebar D&B icon gvr sidebar

We are GDPR and CCPA compliant! Your transaction & personal information is safe and secure.